Picard Medical, Inc. (PMI)
| Market Cap | 20.58M |
| Revenue (ttm) | 6.30M +41.2% |
| Net Income | -26.42M |
| EPS | -17.88 |
| Shares Out | 2.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 349,989 |
| Open | 8.82 |
| Previous Close | 9.09 |
| Day's Range | 8.40 - 9.49 |
| 52-Week Range | 2.65 - 684.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About PMI
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the United States, Europe, and internationally. The company was incorporated in 2021 and is headquartered in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard ... [Read more]
Financial Performance
In 2025, Picard Medical's revenue was $4.94 million, an increase of 12.50% compared to the previous year's $4.39 million. Losses were -$27.00 million, 13.8% more than in 2024.
Financial StatementsNews
Picard Medical Inc trading resumes
09:43 EDT Picard Medical (PMI) Inc trading resumes
Picard Medical Inc trading halted, volatility trading pause
09:38 EDT Picard Medical (PMI) Inc trading halted, volatility trading pause
Picard Medical Reports Second Quarter 2026 Financial Results
- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE A...
Picard Medical Quarterly report: Q2 2026
Picard Medical has published its Q2 2026 quarterly earnings report on August 19, 2026.
Picard Medical Earnings release: Q2 2026
Picard Medical released its Q2 2026 earnings on August 19, 2026, summarizing the period's financial results.
Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– –First public scientific presen...
Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026
-First scientific presentation of the Emperor Drive System architecture to the biomedical engineering community- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: P...
Picard Medical announces NYSE acceptance of plan to regain compliance
Picard Medical (PMI) announced that the NYSE has accepted the company’s plan to regain compliance with the exchange’s continued listing standards under Sections 1003 and of the NYSE American Company…
Picard Medical Receives NYSE American Acceptance of Compliance Plan
-Company continues advancing long-term growth strategy under accepted compliance plan- -Company continues advancing long-term growth strategy under accepted compliance plan-
Picard Medical announces 1-for-50 reverse stock split
Picard Medical (PMI) announced that its Board of Directors has approved the implementation of a 1-for-50 reverse stock split of the Company’s issued and outstanding common stock. As disclosed in…
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
-Reverse stock split to support continued compliance with NYSE American continued listing standards- TUCSON, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Co...
Picard Medical Proxy statement: Proxy filing
Picard Medical filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program
Peer-reviewed journal's News section highlights the Company's continued progress toward a fully implantable total artificial heart Peer-reviewed journal's News section highlights the Company's continu...
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration Presentation Highlights Business Progress, Product Development Milestones, and Matt...
Picard Medical Proxy statement: Proxy filing
Picard Medical filed a proxy statement on July 8, 2026, providing details for shareholder voting and corporate governance matters.
Picard Medical Proxy statement: Proxy filing
Picard Medical filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Picard Medical CEO Patrick Schnegelsberg steps down
Picard Medical (PMI) announced a leadership transition. Patrick Schnegelsberg has stepped down as CEO and as a member of the company’s board of directors, effective June 18. The company said…
Picard Medical Announces Leadership Transition
TUCSON, Ariz., June 24, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the wor...
U.S. Bank Names Eric Levine to Lead Healthcare Payments
MINNEAPOLIS--(BUSINESS WIRE)--Eric Levine has joined U.S. Bank to lead the bank's strategy to deliver more connected treasury, payments and merchant solutions to healthcare organizations. As head of h...
WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future
STAMFORD, CT--(BUSINESS WIRE)--Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organizatio...
Philip Morris International Announces New Regional Leadership
STAMFORD, CT--(BUSINESS WIRE)--Philip Morris International (PMI) (NYSE: PM) announced a series of regional leadership appointments that support its ongoing shift toward a smoke‑free future. Effective ...
Picard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026
TUCSON, Ariz., June 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the wor...
Picard Medical Proxy statement: Proxy filing
Picard Medical filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Picard Medical advances Emperor total artificial heart program
The company states: “Picard Medical (PMI) announced the successful completion of an acute in vivo implant study series using the Company’s next-generation Emperor Total Artificial Heart Platform at th...
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures —